

Published in final edited form as:

Nat Neurosci. 2008 March ; 11(3): 251–253. doi:10.1038/nn2047.

Astrocytes as determinants of disease progression in inherited ALS

Koji Yamanaka^{1,2,6}, Seung Joo Chun¹, Severine Boillee¹, Noriko Fujimori-Tonou², Hirofumi Yamashita², David H. Gutmann³, Ryosuke Takahashi⁴, Hidemi Misawa⁵, and Don W. Cleveland^{1,6}

¹Ludwig Institute for Cancer Research and Department of Medicine and Neuroscience, University of California at San Diego, La Jolla, CA 92093, USA

²Yamanaka Research Unit, RIKEN Brain Science Institute, Wako, Saitama 351-0198, Japan

³Department of Neurology, Washington University School of Medicine, St. Louis, MO 63110, USA

⁴Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, 606-8507, Japan

⁵Department of Pharmacology, Kyoritsu University of Pharmacy, Tokyo 105-8512, Japan

Abstract

Dominant mutations in superoxide dismutase cause amyotrophic lateral sclerosis (ALS), an adult-onset neurodegenerative disease characterized by loss of motor neurons. Using mice carrying a deletable mutant gene, diminished mutant expression in astrocytes did not affect onset, but delayed microglial activation and sharply slowed later disease progression. These findings demonstrate that mutant astrocytes are viable targets for therapies to slow progression of non-cell-autonomous killing of motor neurons in ALS.

Amyotrophic lateral sclerosis (ALS) is an adult-onset neurodegenerative disease, characterized by a progressive, fatal loss of motor neurons. Dominant mutations in the gene for superoxide dismutase (SOD1) are the most frequent cause of inherited ALS. Ubiquitous expression of mutant SOD1 in rodents leads to progressive, selective motor neuron degeneration due to an acquired toxic property(ies). The exact mechanism responsible for motor neuron degeneration in ALS, however, is not known^{1,2}. Mutant damage within the vulnerable motor neurons is a key determinant of disease onset³, while accumulating evidence supports an active role of non-neuronal cells in motor neuron degeneration^{3–7}. Evidence with selective gene excision³ or bone marrow grafting⁵ has demonstrated that mutant SOD1-derived damage within microglia accelerates later disease progression. Despite the importance of astrocyte function, the role of mutant action within astrocytes in disease has not been tested *in vivo*.

To examine whether mutant SOD1 damage within astrocytes contributes to disease, *LoxSOD1^{G37R}* mice³, carrying a mutant SOD1 gene that can be deleted by the action of the Cre recombinase, were mated with GFAP-Cre mice (Supplementary Fig. 1) which express both Cre recombinase and β -galactosidase (LacZ) under the control of the human GFAP promoter⁸. Although this GFAP-Cre transgene is expressed within a subset of neurons in the

⁶Correspondence should be addressed to D.W.C. (dcleveland@ucsd.edu). ⁶K.Y. (kyamanaka@brain.riken.jp).

Author Contributions K.Y., S.J.C., S.B., N.F.-T., and H.Y. conducted the experiments. D.H.G., R.T., and H.M. provided essential experimental tools and advice. K.Y., S.B., and D.W.C. were responsible for the overall design of the project, analyses of the results, and writing the manuscript.

cerebellum and hippocampus during embryogenesis⁹, measurement of β -galactosidase activity (by deposition of a blue reaction product after addition of the X-gal substrate) demonstrated that Cre-mediated recombination was restricted within the spinal cord to GFAP-reactive astrocytes (Fig. 1a,b). Efficiency of mutant gene excision within cultured astrocytes from newborn $\text{LoxSOD1}^{\text{G37R}}/\text{GFAP-Cre}^+$ mice was $\sim 76\%$ (Fig. 1d,e), determined by quantitative PCR for human SOD1 transgene number (Fig. 1d) and immunoblotting for mutant SOD1 levels (Fig. 1e). Neither detectable Cre-activity nor mutant gene excision was observed within microglia (Fig. 1c; Supplementary Fig. 2).

A simple, objective measure of disease onset and early disease was applied by initiation of weight loss, itself reflecting denervation-induced muscle atrophy. Reduction of $\text{SOD1}^{\text{G37R}}$ in astrocytes did not slow disease onset nor early disease (GFAP-Cre^+ : 341.6 ± 48.9 days; GFAP-Cre^- : 337.0 ± 35.8 days; Fig. 1f,h). However, late disease progression (from early disease to end-stage) was sharply delayed, providing a mean extension of survival by 48 days (Cre^+ : 87.4 days; Cre^- : 39.5 days; Fig. 1j). Progression from onset to early disease was more modestly slowed by 14 days (Cre^+ : 99.3 days; Cre^- : 85.2 days; Fig. 1i). Overall survival was extended by 60 days (Cre^+ : 436.5 ± 38.8 days; Cre^- : 376.5 ± 26.9 days; Fig. 1g). This contrasts with delayed disease onset from diminished mutant synthesis solely within motor neurons (with a VAcHT-Cre transgene carrying the motor neuron specific vesicular acetylcholine transporter promoter) without affecting disease progression (Supplementary text and Supplementary Fig. 3), just as reported previously with an *Islet1*-Cre transgene that is expressed within motor neurons and some peripheral tissues³.

Astrocytic and microglial cell activation is a well accepted feature of SOD1 mutant mediated ALS^{1,2}. Appearance of an elevated proportion of GFAP-positive astrocytes initiated prior to disease onset (Fig. 2a) in $\text{LoxSOD1}^{\text{G37R}}$ mice. This astrogliosis was progressive and was readily apparent by onset (Fig. 2b) and more prominent during disease progression (Fig. 2c). Despite substantial mutant reduction, astrogliosis was not, however, different in comparing disease-matched $\text{LoxSOD1}^{\text{G37R}}/\text{GFAP-Cre}^+$ mice (Fig. 2d,e) and $\text{LoxSOD1}^{\text{G37R}}/\text{Cre}^-$ mice (Fig. 2b,c).

Microglial activation initiated at earliest disease onset in Cre^- mice (Fig. 2g) and was progressively more prominent during disease progression (Fig. 2h). Microglial activation was, however, significantly delayed from onset through early disease in the GFAP-Cre^+ mice when mutant SOD1 levels were reduced only in astrocytes (Fig. 2i,j). By exploiting the presence of β -galactosidase to mark astrocytes with diminished SOD1 mutant synthesis, examination of sections throughout lumbar spinal cords of symptomatic $\text{LoxSOD1}^{\text{G37R}}/\text{GFAP-Cre}^+$ mice revealed an inverse relationship (Fig. 3a–g) between the number of astrocytes with reduced mutant SOD1 (Cre^+) and activated microglia (correlation coefficient: $r = -0.868$, $p < 0.001$), despite comparable astrocytic activation. Thus, microglial activation was most prominent in areas with the highest mutant SOD1-expressing astrocyte concentration.

Elevated production of nitric oxide by upregulated inducible nitric oxide synthase (iNOS) synthesis has been reported in mutant SOD1 mice¹⁰, albeit deletion of the iNOS gene has modest¹¹ or no¹² effect on SOD1-mediated disease. It is not known in which glial cells this nitric oxide is produced in *in vivo* models of ALS, although both microglia and astrocytes have an ability to produce it when stimulated *in vitro*¹³. Triple staining of lumbar spinal cord sections with iNOS, Mac2, and GFAP antibodies revealed that almost all iNOS-positive cells were Mac2-positive microglia (Fig. 3n–r; Supplementary Fig. 4), indicating that activated microglia are the primary cell type producing nitric oxide in this SOD1 mouse model. Diminishing mutant synthesis within astrocytes inhibited iNOS induction in disease

matched, symptomatic SOD1 mice (Fig. 3h,k), in accord with significant inhibition of microglial activation (Fig. 3i,l).

A role of astrocytes in inherited ALS has been previously raised in several contexts. Mutant expressing astrocytes produce and release one or more as yet uncharacterized components that can accelerate motor neuron death *in vitro*^{6, 7}. Focal loss of the astrocytic EAAT2 glutamate transporter within affected regions¹⁴ (Supplementary Fig. 5) and the failure to increase glutamate uptake in SOD1^{G93A} astrocytes *in vitro*¹⁵ support glutamate dependent excitotoxicity as a component of disease. Nevertheless, diminished mutant SOD1 synthesis within most astrocytes did not affect disease dependent loss of EAAT2 from those astrocytes (Supplementary Fig. 5), demonstrating that reduction in glutamate transport reflects non-cell autonomous damage to astrocytes, in part, from mutant SOD1 synthesized by other cells. Our use of selective gene excision has now demonstrated that mutant SOD1 damage within both microglia³ and astrocytes (Fig. 1g–j), accelerates later disease progression, without affecting initiation of motor neuron degeneration and phenotypic disease onset. Discovery that damage within astrocytes determines the timing of microglial activation and infiltration provides a further insight that beyond any direct effect of mutant astrocytes on motor neurons such astrocytes amplify an inflammatory response from microglia (through production of nitric oxide and toxic cytokines), leading to further damage to the motor neurons and accelerated disease progression through a non-cell autonomous mechanism (Supplementary Fig. 6). These findings validate therapies, including astrocytic stem cell replacement approaches, to slow disease progression in ALS by supplementing healthy astrocytes or modulating toxicity within astrocytes to control an inflammatory response of microglia.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by NIH Grant (NS 27036) and a grant from the Packard ALS Center at Johns Hopkins (to D.W.C.), as well as MDA Developmental Grant, Uehara Memorial Foundation, Nakabayashi Trust for ALS Research, and Grant-in-aid for Scientific Research (19591021) and on Priority Area (19044048) from MEXT, Japan (to K.Y.). Salary support for D.W.C is provided by the Ludwig Institute for Cancer Research. S.B. is a recipient of a Fondation pour la Recherche Medical fellowship, an INSERM fellowship, and a MDA Developmental Grant.

References

1. Pasinelli P, Brown RH. *Nat Rev Neurosci.* 2006; 7:710–723. [PubMed: 16924260]
2. Boillee S, Vande Velde C, Cleveland DW. *Neuron.* 2006; 52:39–59. [PubMed: 17015226]
3. Boillee S, et al. *Science.* 2006; 312:1389–1392. [PubMed: 16741123]
4. Clement AM, et al. *Science.* 2003; 302:113–117. [PubMed: 14526083]
5. Beers DR, et al. *Proc Natl Acad Sci U S A.* 2006; 103:16021–16026. [PubMed: 17043238]
6. Di Giorgio FP, Carrasco MA, Siao MC, Maniatis T, Eggan K. *Nat Neurosci.* 2007; 10:608–614. [PubMed: 17435754]
7. Nagai M, et al. *Nat Neurosci.* 2007; 10:615–622. [PubMed: 17435755]
8. Bajenaru ML, et al. *Molecular and cellular biology.* 2002; 22:5100–5113. [PubMed: 12077339]
9. Fraser MM, et al. *Cancer research.* 2004; 64:7773–7779. [PubMed: 15520182]
10. Almer G, Vukosavic S, Romero N, Przedborski S. *J Neurochem.* 1999; 72:2415–2425. [PubMed: 10349851]
11. Martin LJ, et al. *The Journal of comparative neurology.* 2007; 500:20–46. [PubMed: 17099894]
12. Son M, Fathallah-Shaykh HM, Elliott JL. *Ann Neurol.* 2001; 50:273. [PubMed: 11506415]

13. Barbeito LH, et al. *Brain research*. 2004; 47:263–274.
14. Howland DS, et al. *Proc Natl Acad Sci U S A*. 2002; 99:1604–1609. [PubMed: 11818550]
15. Vermeiren C, et al. *J Neurochem*. 2006; 96:719–731. [PubMed: 16371010]




Figure 1. Selective Cre-mediated gene excision demonstrates mutant SOD1 action within astrocytes to be a primary determinant of later disease progression
(a,b) β -galactosidase (β -gal) activity within astrocytes in **(a)** whole or **(b)** anterior horn region of the lumbar spinal cord section of GFAP-Cre/Rosa26 reporter mice visualized with X-gal and immunostaining with GFAP antibody. (Inset) Magnified image of the boxed area in **(b)**. Arrows indicate β -Gal/GFAP-Cre expressing astrocytes. **(c, d)** *LoxSOD1^{G37R}* transgene levels ($n=3$ for each group) in **(c)** primary microglia or **(d)** astrocytes from *LoxSOD1^{G37R}/GFAP-Cre⁺* and *LoxSOD1^{G37R}* mice using real-time PCR. **(e)** *SOD1^{G37R}* and mouse *SOD1* content determined by immunoblotting in extracts from isolated primary astrocytes of (lanes 1, 2) *LoxSOD1^{G37R}/GFAP-Cre⁺* and (lanes 3–5) a dilution series of a comparable extract from *LoxSOD1^{G37R}* astrocytes representing 25%, 50% and 100% of the protein amounts loaded in lanes 1 and 2. Ages at which **(f)** early disease phase (to 10% weight loss) ($p=0.76$) or **(g)** end-stage ($p<0.0001$) was reached for (red) *LoxSOD1^{G37R}/GFAP-Cre⁺* mice and (blue) *LoxSOD1^{G37R}* littermates. Mean ages \pm standard deviation were provided. **(h–j)** Mean onset ($p=0.47$) **(h)**, mean duration of early disease ($p=0.35$) **(i)** (from onset to 10% weight loss) and a later disease ($p<0.0001$) **(j)** (from 10% weight loss to end-stage) for (red) *LoxSOD1^{G37R}/GFAP-Cre⁺* and (blue) *LoxSOD1^{G37R}* littermates. At each time point, p value was determined by unpaired t test. Error bars denote standard deviation.




Figure 2. Selective downregulation of mutant SOD1 in astrocytes significantly inhibits microglial activation

(a–e) GFAP detected within astrocytes, (f–j) Mac2-positive activated microglia, and (k–o) motor neurons identified with the neurofilament antibody SMI-32 staining in the lumbar spinal cord of a *LoxSOD1^{G37R}* mouse (a, f, k, p) prior to disease onset, (b, g, l, p) at disease onset, or (c, h, m, r) at early disease, together with *LoxSOD1^{G37R}/GFAP-Cre⁺* mice (d, i, n, s) at onset or (e, j, o, t) early disease. (p–t) Merged images.




Figure 3. Mutant-expressing astrocytes enhance microglial activation and induction of iNOS (a–f) Images of (a, d) β -galactosidase, (b, e) Mac2, and (c, f) GFAP staining from a (a–c) left and (d–f) right lumbar spinal cord section from a 12-month-old $\text{LoxSOD1}^{\text{G37R}}/\text{GFAP-Cre}^+$ mouse. (a, d) GFAP- Cre^+ astrocytes are marked by β -galactosidase. (g) Inverted correlation between the number of Cre-positive astrocytes and Mac2-positive microglia in $\text{LoxSOD1}^{\text{G37R}}/\text{GFAP-Cre}^+$ mice lumbar spinal cord sections. Correlation coefficient $r = -0.868$ ($p < 0.001$). (h–m) Lumbar spinal cord sections from (h–j) $\text{LoxSOD1}^{\text{G37R}}$ and (k–m) $\text{LoxSOD1}^{\text{G37R}}/\text{GFAP-Cre}^+$ mice at early disease stage immunostained with antibodies to (h, k) iNOS, (i, l) Mac2, and (j, m) GFAP. (n) Quantification of iNOS-positive cells within anterior horn from lumbar spinal cord of symptomatic $\text{LoxSOD1}^{\text{G37R}}$ mice. Averaged percent of $\text{iNOS}^+/\text{Mac2}^+$ (red), $\text{iNOS}^+/\text{GFAP}^+$ (blue), and $\text{iNOS}^+/\text{other}$ cell type (black) per total iNOS^+ cells was plotted. (o–r) Magnified images of anterior horn from lumbar spinal cord of symptomatic $\text{LoxSOD1}^{\text{G37R}}$ mice stained with (o) iNOS, (p) Mac2, and (q) GFAP. (r) Merged image illustrates that iNOS positive cells are Mac2-positive microglia.